Deutsch
 
Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
Zur Ablage hinzufügen
  Lokale TagsFreigabegeschichteDetailsÜbersicht

Freigegeben
Zeitschriftenartikel

Photodynamic Opening of the Blood–Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors

Urheber*innen

Semyachkina-Glushkovskaya,  Oxana
External Organizations;

Terskov,  Andrey
External Organizations;

Khorovodov,  Alexander
External Organizations;

Telnova,  Valeria
External Organizations;

Blokhina,  Inna
External Organizations;

Saranceva,  Elena
External Organizations;

/persons/resource/Juergen.Kurths

Kurths,  Jürgen
Potsdam Institute for Climate Impact Research;

Externe Ressourcen
Es sind keine externen Ressourcen hinterlegt
Volltexte (frei zugänglich)
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Semyachkina-Glushkovskaya, O., Terskov, A., Khorovodov, A., Telnova, V., Blokhina, I., Saranceva, E., Kurths, J. (2022): Photodynamic Opening of the Blood–Brain Barrier and the Meningeal Lymphatic System: The New Niche in Immunotherapy for Brain Tumors. - Pharmaceutics, 14, 12, 2612.
https://doi.org/10.3390/pharmaceutics14122612


Zitierlink: https://publications.pik-potsdam.de/pubman/item/item_27962
Zusammenfassung
Photodynamic therapy (PDT) is a promising add-on therapy to the current standard of care for patients with glioblastoma (GBM). The traditional explanation of the anti-cancer PDT effects involves the PDT-induced generation of a singlet oxygen in the GBM cells, which causes tumor cell death and microvasculature collapse. Recently, new vascular mechanisms of PDT associated with opening of the blood–brain barrier (OBBB) and the activation of functions of the meningeal lymphatic vessels have been discovered. In this review, we highlight the emerging trends and future promises of immunotherapy for brain tumors and discuss PDT-OBBB as a new niche and an important informative platform for the development of innovative pharmacological strategies for the modulation of brain tumor immunity and the improvement of immunotherapy for GBM.